A new era of antithrombotic therapy in patients with atrial fibrillation

Harsh Golwala, Chadi Dib, Alfonso Tafur, Mazen S. Abu-Fadel

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Atrial fibrillation/flutter is the most common cardiac arrhythmia that can potentially result in stroke and death. For many years, aspirin and warfarin have been the cornerstone of stroke prevention among such patients. Although warfarin therapy has been advocated for patients with high likelihood of stroke, it requires close surveillance and monitoring, has a narrow therapeutic window and is quite often affected by medication interactions and diet. Thus, the need for a better and more consistent anticoagulant therapy was necessary and has been under development with various successes for many years. This article will review 3 new antithrombotic medications that may potentially become the mainstay for treatment of patients with atrial fibrillation in the near future.

Original languageEnglish (US)
Pages (from-to)128-135
Number of pages8
JournalAmerican Journal of the Medical Sciences
Issue number2
StatePublished - Aug 2012
Externally publishedYes


  • Apixaban
  • Atrial fibrillation
  • Dabigatran
  • Newer anticoagulants
  • Rivaroxaban

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'A new era of antithrombotic therapy in patients with atrial fibrillation'. Together they form a unique fingerprint.

Cite this